GlassScriptPhysician profile
William J Schmalz
NPI 1336255900
$36,938.51
in general payments reported to CMS, 2019-2025
60 companies · $20.98 in 2025
The $20.98 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $9,593 · 2021: $4,259 · 2022: $3,613 · 2023: $59.15 · 2025: $20.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $80.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $80.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $17,179.94 | 2019-2022 | |
| Abbvie INC. | $5,409.45 | 2019-2022 | |
| Amgen INC. | $2,134.43 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,469.17 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $1,083.49 | 2019-2022 | |
| Glaxosmithkline, LLC. | $1,083.08 | 2019-2022 | |
| Lilly USA, LLC | $632.53 | 2019-2022 | |
| Novo Nordisk INC | $613.82 | 2019-2022 | |
| Allergan, INC. | $572.42 | 2019-2020 | |
| Ucb, INC. | $558.26 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $485.16 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Takeda Pharmaceuticals U.S.A., INC. | $468.85 | 2019-2022 | |
| Pfizer INC. | $465.93 | 2019-2022 | |
| Corcept Therapeutics | $406.78 | 2019-2022 | |
| Eisai INC. | $401.20 | 2020-2022 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Schmalz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.